Overview

Bioequivalence Study of Two Products of Apixaban 5mg Tablets in Healthy, Adult, Human Subjects

Status:
Completed
Trial end date:
2023-04-27
Target enrollment:
Participant gender:
Summary
To compare the bioavailability and characterize the pharmacokinetic profile of the sponsor's test product relative to that of reference product after single oral dose administration in normal, healthy, adult, human subjects under fasting condition and to assess the bioequivalence.
Phase:
Phase 1
Details
Lead Sponsor:
Humanis Saglık Anonim Sirketi
Treatments:
Apixaban